Amid the third wave of COVID-19 outbreak in Hong Kong, the CU Medicine team recruited 55 hospitalised patients with COVID-19; 25 patients were treated with the microbiome immunity formula and 30 received standard care. Key findings are as follow:
- 100% of patients treated with the microbiome immunity formula achieved complete resolution of symptoms compared with half in the control group by week 2.
- 88% of patients in the microbiome immunity formula group developed neutralizing antibody compared with 63% in the control group.
- The blood level of pro-inflammatory cytokines was significantly reduced in the microbiome immunity formula group, indicating that inflammation was under control.
- The levels of favourable bacteria recovered from stool in patients receiving the microbiome immunity formula was significantly increased, suggesting that the formula could restore gut dysbiosis.
And to evaluate the extent of dysbiosis in the general population, CU Medicine studied 1,000 subjects in Hong Kong aged between 18 and 83 and found that almost 40% of them had significant dysbiosis (i.e., impaired immunity) comparable to that of COVID-19 patients.
Read More﹕40% of Hong Kong People Show Gut Dysbiosis Comparable to that of COVID-19 Patients CUHK Microbiome Immunity Formula Hastens Recovery of COVID-19 Patients and Offers Hope to Boost Immunity
Read More﹕Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study
Have you ever thought about why some people are more vulnerable to catching a virus? And why some get more severe infection than others? Gut microbiota, which is a fine
balance between good and bad bacteria, regulates our immune system. Imbalance in gut
Read More﹕CU Medicine Develops a Probiotic Formula to Target Imbalance in Gut Microbiota in COVID-19